Cheryl Forder

AZD5438, a potent oral inhibitor of cyclin-dependent kinases 1, 2, and 9, leads to pharmacodynamic changes and potent antitumor effects in human tumor xenografts

Kate F. Byth, Andrew P. Thomas, Gareth Hughes et al. · Molecular Cancer Therapeutics · 2009 · 122 citations

Medicine, Oncology, Pharmacology +17

Evidence for Heterotypic Interaction between the Receptor Tyrosine Kinases TIE-1 and TIE-2

Marie B. Marron, David P. Hughes, Michael D. Edge et al. · Journal of Biological Chemistry · 2000 · 96 citations · Full text

Life Sciences, Cell Biology, Molecular Biology +17

The cellular phenotype of AZ703, a novel selective imidazo[1,2-<i>a</i>]pyridine cyclin-dependent kinase inhibitor

Kate F. Byth, Catherine Geh, Cheryl Forder et al. · Molecular Cancer Therapeutics · 2006 · 48 citations · Full text

Medicine, Oncology, Pharmacology +15

A phase I pharmacodynamic study of the effects of the cyclin-dependent kinase-inhibitor AZD5438 on cell cycle markers within the buccal mucosa, plucked scalp hairs and peripheral blood mononucleocytes of healthy male volunteers

D. Ross Camidge, Jim Growcott, Dereck D. Amakye et al. · Cancer Chemotherapy and Pharmacology · 2006 · 26 citations

Life Sciences, Cell Biology, Pharmacology +16